▶주메뉴 바로가기
▶본문 바로가기
Celltrion announced on Aug. 1 that it had started a phase 3 clinical trial of its new drug Remsima SC in the US. Remsima SC is a subcutaneous version of Remsima, the Korean company’s biosimilar of Johnson & Johnson’s autoimmune disease therapy Remicade. According to the company, the new pen-type...
South Korean pharmaceutical firm Samsung Bioepis said on July 24 it has won approval from the US Food and Drug Administration to sell one of its biosimilars in the United States. Hadlima, referencing AbbVie’s blockbuster autoimmune treatment Humira, can be also used for treatment of diseases t...
The value of stocks owned by both former and current entertainment agency owners in South Korea dropped nearly 30 percent compared to last year, data showed on July 21, as the industry is struggling to cope with a slew of scandals as well as trade tensions between Korea and Japan, a key market. Ac...
Three-dimensional printing of human organs is not some far-fetched fiction. Active research of the relevant technologies has gained pace around the globe, especially here in South Korea, where the academia, industry and government are paying keen attention to the convergence of medicine, mechanical...
South Korean biopharma firms Chong Kun Dang and Dong-A ST expect to launch their biosimilars in Japan without a headwind, despite escalating trade strife, as their drugs will be represented by Japanese partner firms. The erythropoietin drug Nesp, for which the patent expires in Japan this year...
Celltrion announced July 19 that it has established the joint venture Vcell Healthcare in Shanghai with Hong Kong-based conglomerate Nan Fung Group to make a foray into China. Established in 1954, Nan Fung Group’s businesses range from real estate development to life sciences. “We are now one s...
HanAll Biopharma , a subsidiary of Daewoong Pharmaceutical, invested 5.6 billion won ($4.76 million) in Switzerland-based biotech startup Roivant Sciences’ subsidiary Immunovant Sciences, according to industry sources on July 19. In return, the Korean company gained a stake in Immunovant Science...
Korean biotech firm Bridge Biotherapeutics announced on July 18 that it has signed a contract with German-based pharmaceutical company Boehringer Ingelheim to license out its drug candidate BBT-877. BBT-877 is expected to be developed to treat various fibrotic diseases such as idiopathic pulmonary...
The prosecution has requested arrest warrants for Kim Tae-han, CEO of contract drug manufacturer Samsung BioLogics, and two other executives, surnamed Kim and Shim. The Seoul Central District Court will review the request on July 19. Prosecutors had requested arrest warrants in May, but the court ...
Kim Tae-han, president and CEO of contract drug manufacturer Samsung BioLogics, appeared again before prosecutors on July 5 to be questioned about whether he abetted the destruction of evidence in an accounting scandal at the company. Kim, who has headed the Samsung Group company since its foun...
South Korea’s drug authorities on July 3 revoked the permit for gene therapy drug Invossa for mislabeling and the false reporting of an ingredient used. The Ministry of Food and Drug Safety said it made the final decision banning the production and sales of Invossa after it canceled the licens...
Thinking of undergoing vision-sharpening surgery but scared if things would go awry as you grow older? Taking cue of such concerns among people contemplating lasik surgery, genetic services provider Avellino Labs, headquartered in Palo Alto, California, has developed a DNA diagnostic kit which the ...
Shares of Kolon Group ’s bio affiliates plummeted after South Korea’s drug authorities canceled the license for gene therapy drug Invossa on May 28. According to the Ministry of Food and Drug Safety, the decision was made as the drug maker intentionally mislabeling an ingredient used in its ne...
Korean new drug developer Syntekabio is preparing to go public, after receiving approval for a drug candidate from CJ Healthcare, according to industry sources on May 20. The company has picked KB Securities as its IPO manager. Syntekabio is hoping to go public before the year-end but declined to ...
Prosecutors raided a task force office of Samsung Electronics on May 16 as part of an investigation into allegations that Samsung Group may have ordered accounting fraud by its biopharmaceutical unit. The investigators were sent to the task force office in charge of business support work for ch...
Posco threads new life to old uniforms for Philippine communities
NCSoft releases sustainability report to meet global green standards
Samsung may supply advanced image sensors for Apple: analyst
Hana chief cleared of severe punishment in DLF crisis
NCSoft launches official Discord channel for Throne and Liberty
Qoo10 liquidity crisis sparks massive complaints, fears of wider damage